Synthesis and muscarinic activities of O-[(Benzyl- or benzoyl-pyrazolyl)propynyl]-oximes of N-methylpiperidinone, 3-tropinone, and 3-quinuclidinone
- 15 May 2003
- journal article
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 11 (10) , 2263-2268
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Muscarinic Receptor Agonists and AntagonistsMolecules, 2001
- M1 Muscarinic Agonists as Potential Disease‐Modifying Agents in Alzheimer's Disease: Rationale and PerspectivesAnnals of the New York Academy of Sciences, 2000
- Treatment with the Selective Muscarinic Agonist Talsaclidine Decreases Cerebrospinal Fluid Levels of Total Amyloid β‐Peptide in Patients with Alzheimer's DiseaseAnnals of the New York Academy of Sciences, 2000
- Muscarinic agonists reduce tau phosphorylation in non-neuronal cells via GSK-3β inhibition and in neuronsJournal of Neural Transmission, 2000
- N-Benzylpiperidine derivatives of 1,2,4-thiadiazolidinone as new acetylcholinesterase inhibitorsEuropean Journal of Medicinal Chemistry, 2000
- Muscarinic M1 agonists in the treatment of Alzheimer’s diseaseExpert Opinion on Investigational Drugs, 2000
- CI-1017, a functionally M1-selective muscarinic agonist: design, synthesis, and preclinical pharmacologyPharmaceutica Acta Helvetiae, 2000
- Therapeutic Strategies in Alzheimer’s Disease: Ml Muscarinic AgonistsThe Japanese Journal of Pharmacology, 2000
- Muscarinic m1 receptor agonists increase the secretion of the amyloid precursor protein ectodomainLife Sciences, 1997
- M1 Agonists for the Treatment of Alzheimer's Disease.Annals of the New York Academy of Sciences, 1996